A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
The CDMO Division of Lubrizol Life Science Health (LLS Health) is a pharmaceutical contract development and drug product manufacturing organization that offers a range of technical capabilities, multiple technology platforms, and expertise in complex drug delivery.
LLS Health offers R&D formulation and clinical/commercial drug product manufacturing supported by analytical testing, ICH stability programs, and HPAPI/controlled substance handling. Its technology-agnostic team offers expertise in solubility and bioavailability enhancement, sterile and aseptic manufacturing, and long-acting injectables and implantables.
Contract Pharma recently caught up with the president of LLS Health, Rob Lee, and talked about the CDMO’s continued growth alongside the rise of biologics and parenteral drug delivery and technology trends in general.